‹ ›
MYP_023005
← PREVIOUS NEXT → BACK
Basic Information
P45(derived from E2 envelope protein of GB virus C)
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
18 amino acids
C83H130N22O31S
Standard
Sequence
SDRDTVVELSEWGVPCAT
Physicochemical Analysis
1964.11 Da
4.05
-3.54
-3.77
-0.1968
-0.21
0.38
0.02
0.01
75.56
0.0556
5500.00
5500.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
857.04
-9.85
31.0
29.0
60.0
137.0
3.0
17.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0096821 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1
505.5 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperEffect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. | Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. | J Med Chem. 2010 Aug 26;53(16):6054-63. | DOI:10.1021/jm100452c | PMID:20718496 PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0099749 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1
48.8 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperEffect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. | Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. | J Med Chem. 2010 Aug 26;53(16):6054-63. | DOI:10.1021/jm100452c | PMID:20718496 PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0220163 VERIFIED: YES
Provenance & Taxonomy
not reported [other]
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
PaperHIPdb: a database of experimentally validated HIV inhibiting peptides PMID23359817 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23359817/
RECORD: Rec_0231126 VERIFIED: YES
Provenance & Taxonomy
GB virus C [Virus]
54290
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
CEM-174
50 %
Inhibition
PaperEffect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
RECORD: Rec_0247377 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
PMID20718496 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/20718496/
FIRST PREV 1 2 3 NEXT LAST
Showing 5 records on this page · Page 2 of 3